+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are conducting a large prospective, observational cohort study to evaluate the clinical impact of new Monoclonal Antibodies MAB in patients with B-cell Non-Hodgkin Lymphoma NHL treated in Italian clinical practice. The study focuses on collecting information about the use, feasibility, effectiveness, and both short- and long-term side effects of novel MABs that have been approved by the European Medicines Agency since 2020 and prescribed according to authorized indications in Italy. Participants will be divided into groups based on treatment indication, antibody type, and lymphoma subtype to allow detailed analysis. The study observes patients with B-cell NHL who have received at least one dose of a novel MAB either alone or in combination, as authorized for use in Italy. Both patients receiving first-line treatment and those with relapsed or refractory disease are included. Various cohorts and sub-cohorts will be analyzed to understand outcomes by indication, antibody type, and histological subtype, providing a comprehensive overview of these treatments in real-life settings. Participants will be followed for at least five years to assess outcomes such as overall response rate, complete response rate, progression-free survival, overall survival, event-free survival, time to next treatment, non-relapse mortality, duration of response, and the incidence of early and late adverse events. Clinical data collection will include treatment details, safety monitoring, and long-term follow-up to evaluate both effectiveness and toxicity. The study spans several years, allowing researchers to capture extensive real-world evidence on novel MAB use in B-cell NHL.

Age: 18Years +All Genders
61 locations
P

Actively Recruiting

Researchers are conducting the PERSEUS Registry to observe adults diagnosed with acute pulmonary embolism PE. This registry collects detailed information from initial emergency response, emergency department visits, hospital stay including the first 48 hours of treatment, and long-term follow-up up to five years. The study aims to understand routine care approaches and outcomes such as mortality, disease complications, and how existing risk assessment tools perform in real-world settings. The study includes two groups a retrospective cohort with patients diagnosed from January 2023 until local ethics approval, and a prospective cohort enrolling newly diagnosed patients for five years following approval. Data collected include pre-hospital emergency care, hospital diagnostics and treatments, hemodynamic and respiratory changes during the acute phase, hospital discharge outcomes, and long-term follow-up through various contact methods or medical record review. Participants receive routine care without changes from the study. Information such as vital signs, imaging, laboratory tests, and clinical events are recorded. Follow-up assessments track survival, recurrence, bleeding events, functional limitations, and development of chronic complications. Data privacy is maintained with pseudonymization, and quality checks are regularly performed. The study continues until 2032, with primary outcomes focusing on mortality at 30 days after diagnosis.

Age: 18Years +All Genders
16 locations